Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -252.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -252.96% |
| Mar 31, 2026 | -195.02% |
| Dec 31, 2025 | -226.65% |
| Sep 30, 2025 | -13.50% |
| Jun 30, 2025 | 59.44% |
| Mar 31, 2025 | 246.58% |
| Dec 31, 2024 | 192.43% |
| Sep 30, 2024 | 31.60% |
| Jun 30, 2024 | 13.84% |
| Mar 31, 2024 | 0.17% |
| Dec 31, 2023 | -8.02% |
| Sep 30, 2023 | -27.70% |
| Jun 30, 2023 | -32.90% |
| Mar 31, 2023 | -32.65% |
| Dec 31, 2022 | -31.69% |
| Sep 30, 2022 | -37.59% |
| Jun 30, 2022 | -46.16% |
| Mar 31, 2022 | -110.06% |
| Dec 31, 2021 | -95.98% |
| Sep 30, 2021 | -211.01% |